Exelixis Says Takeda Receives Approval For Cabometyx In Japan – Quick Facts

This post was originally published on this site

(RTTNews) – Exelixis, Inc. (EXEL) said Friday that Takeda Pharmaceutical Co. Limited (TKPHF.PK, TAK) has received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market Cabometyx (cabozantinib) as a treatment for patients with unresectable hepatocellular carcinoma (HCC) that has progressed after prior systemic…

Bastion Balance Seoul, Korea.